Last reviewed · How we verify

Dehydrated Alcohol Injection, USP — Competitive Intelligence Brief

Dehydrated Alcohol Injection, USP (Dehydrated Alcohol Injection, USP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sclerosing agent / Ablative agent. Area: Oncology / Interventional Radiology.

phase 3 Sclerosing agent / Ablative agent Oncology / Interventional Radiology Small molecule Live · refreshed every 30 min

Target snapshot

Dehydrated Alcohol Injection, USP (Dehydrated Alcohol Injection, USP) — Ablative Solutions, Inc.. Dehydrated alcohol causes tissue ablation and coagulation necrosis through protein denaturation and cellular dehydration when injected directly into target tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dehydrated Alcohol Injection, USP TARGET Dehydrated Alcohol Injection, USP Ablative Solutions, Inc. phase 3 Sclerosing agent / Ablative agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sclerosing agent / Ablative agent class)

  1. Ablative Solutions, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dehydrated Alcohol Injection, USP — Competitive Intelligence Brief. https://druglandscape.com/ci/dehydrated-alcohol-injection-usp. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing